Dry Eyes Clinical Trial
Official title:
Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
Dry eye clinical research is limited to follow up of disease progression. While a large
catalogue of tests, such as corneal staining grading, tear break up time (TBUT) and
Schirmer's test, is available, objective assessments demonstrate poor to moderate
repeatability. Among these assessments, TBUT has the best repeatability while the Schirmer's
test shows good repeatability for more severe forms of the disease.1 As such, currently,
most research outcomes are based on subjective patient complaints rather than objective
assessment of the condition.
LipiView Ocular Surface Interferometer (LipiView) is a HSA-approved imaging device that has
the ability to assess optical interference pattern produced by light reflected off the tear
film in a safe and non-invasive manner.2 Software analysis of the image then measures the
tear LLT, which is used to objectively quantify the diagnosis of lipid-deficient dry eye.
This current study aims to investigative the inter and intra-examiner reproducibility of
measuring tear lipid layer thickness (LLT) with LipiView, which is used in our current
clinical setting. LipiView has not been evaluated on its reproducibility of measuring tear
lipid layer thickness. The study will also assess for correlation between the magnitude of
tear LLT and the inter and intra-examiner reproducibility of LipiView.
Once this method is found to be repeatable, this can be used in future clinical settings and
trials as an additional tool to investigate dry eye treatments.
This study will be conducted in compliance with the protocol, SGCP and the applicable
regulatory requirements.
Dry eye is a condition that affects 5-35% of the population.11 Common symptoms of this
condition include eye irritation, heaviness of the eyelids, visual disturbances, tearing and
light sensitivity.12 This significantly impacts the quality of life and vision of dry eye
patients. In addition, there is a significant socioeconomic burden. In 2009, 54,051 patients
sought treatment for dry eye in the Singapore National Eye Centre (SNEC). In total, the
costs for dry eye medication amounted to $181,354.17.14 Additionally, dry eye affects work
productivity which further adds on to the socioeconomic burden.15
Currently, the diagnosis and assessment of dry eye is hindered by tests that have poor
repeatability, some of which cause discomfort due to their invasiveness. As a result most
clinical studies involving dry eye treatment rely on symptomatic improvements as a primary
outcome measure. However, symptomatic improvements are a poor measure in determining
treatment effectiveness because with disease progression, the eye becomes desensitized from
nerve damage. Also, it is common for patients to feel a reduction of discomfort of the eye
before objective improvements can be noted by the clinician. An assessment based on symptoms
alone is therefore inappropriate.13
Over the last few years, SNEC/SERI has built up a dedicated team of dry eye researchers for
trials and evaluation of diagnostic devices. There is an increasing interest
internationally, especially from industry, to partner us for testing of commercial products.
The LipiView Ocular Surface Interferometer is a HSA-approved imaging device that allows
clinicians evaluate the characteristics and thickness of the tear lipid layer thickness
(LLT) in a safe and non-invasive manner. The device utilizes white light from a LED source
that is directed at the tear film over the inferior corneal region. Reflected light is
captured by a high resolution camera and the optical inference pattern is evaluated by
software to determine the LLT. 2 It also was found to correlate with other dry eye
diagnostic tests, such as tear film break-up time (TBUT), Schirmer's test and corneal
staining 3,4,5,6. LLT is also reported to better correlate with symptoms than other
objective dry eye tests. 2
While several studies have investigated and shown the association between dry eye syndrome
and low LLT 2,7,8,9, it is not known if LipiView would be able to make reproducible
measurements of LLT for the objective diagnosis of dry eye syndrome.
Clinical importance Should this modality of imaging be shown to be repeatable, it can be
incorporated into current protocol/workflow for assessment and monitoring of dry eye and
treatment progress in our centre, as well as enhancing our capability to perform clinical
trials and increase our international reputation.
Study Objectives and Purpose The primary purpose is to evaluate intra-examiner repeatability
of the LipiView Ocular Surface Interferometer (LipiView) for imaging tear lipid layer
thickness.
Study design:
Prospective study
Rationale:
Repeatability is an important issue in the objective assessment of dry eye. There is lack of
studies that investigate LipiView for assessment of the tear film lipid layer thickness in
dry eyes. LipiView is potentially useful as a non-invasive procedure for objective
measurements of dry eyes.
Methods:
Participants and target sample size 20 healthy volunteers will be recruited for this study.
During recruitment, a simple questionnaire is given to confirm for the absence of any dry
eye symptoms. Each volunteer will also be given a study serial number to ensure anonymity.
All 20 volunteers will participate in the LipiView repeatability and inter-rater agreement
study.
Visit schedules One visit is required for participants.
Duration of study:
10 months.
Procedures:
1. Assessment of Dry Eye Symptoms Participants will be asked to score and fill up a dry
eye questionnaire that assesses the symptomatic severity of dry eyes in the participant
and the extent of its disruption to daily activities. Basic biodata such as age, race,
gender will also be recorded.
2. LipiView Ocular Surface Interferometer Tear Lipid Layer Thickness Measurement During
the measurement of each eye, the participants place their chins on a chin rest and look
at a single white light source for 30 seconds. During this period, participants are
encouraged to blink freely at a comfortable rate which the assessor measures the LLT.
Afterwards, the aforementioned steps will be repeated for the same eye by another
assessor after a 5 minutes interval. Assessor 1 will perform the measurement at time 0
min, 10min and 20min while Assessor 2 will perform the measurement at time 5 min, 15
min, 25min.
Similar steps would be taken for the other eye. Therefore, 12 measurements would be
taken altogether per participant. Between measurements, participants are advised not to
rub or touch their eyes, or instill any eye drops or ointment.
Assessment of fluorescein tear break up time and corneal staining will be conducted
only after LipiView LLT measurement.
3. Fluorescein Dye Tear Break-up Time (TBUT) Fluorescein dye is introduced onto the lower
eyelid by a wetted fluorescein strip. The tear film will then be observed with blue
light using a slit lamp to the point where it breaks. The time from the previous blink
to the breaking of the tear film will be recorded to the nearest second.
4. Fluorescein Dye Corneal Staining After fluorescein dye is introduced, the cornea will
be examined for green stains indicating epithelial erosion, a sign of damage due to
dryness. The number of green stains and their location on the cornea (superior,
central, inferior, temporal, nasal fields) will be recorded.
;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01988597 -
Dry Eye Symptoms and Quality of Life
|
N/A | |
Completed |
NCT01933178 -
Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis
|
N/A | |
Withdrawn |
NCT02123147 -
Examining the Immunological Process of Autoimmune Patients
|
N/A | |
Terminated |
NCT01450787 -
Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics
|
N/A | |
Completed |
NCT06071780 -
Virgin Coconut Oil Contact Lens as Ocular Rewetting Agent
|
N/A | |
Recruiting |
NCT02306668 -
Ocular Surface Dry Eye Microbiome
|
N/A | |
Completed |
NCT01918410 -
Effect of Contact Lens With Alginic Acid in Dry Eye Patients
|
N/A | |
Completed |
NCT01991132 -
Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands
|
N/A | |
Completed |
NCT01679015 -
Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes
|
N/A | |
Completed |
NCT01682460 -
Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
|
Phase 4 | |
Completed |
NCT01695668 -
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
|
N/A | |
Enrolling by invitation |
NCT02153515 -
Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood
|
Phase 3 |